Post-transplant Lymphoproliferative Disease


Post-transplant lymphoproliferative diseases (PTLDs) are the most frequent malignant disorders after solid-organ transplantation in children. Although morphologically often indistinguishable from de novo lymphomatous diseases, per definition, every lymphoproliferation arising after transplantation is considered a PTLD. Because pathogenesis in the context of immunosuppression, viral infection, and treatment differ from lymphomas in immunocompetent patients, PTLD needs to be considered as its own disease entity. Thus the World Health Organization (WHO) recognizes PTLD as a separate group of lymphomas with distinct subclassifications.


The pathophysiology of PTLD is only partially understood, and its cause is most probably multifactorial ( Fig. 28.1 ). Despite all uncertainties, Epstein-Barr virus (EBV) infection (and/or reactivation) and immunosuppression necessary to maintain graft tolerance are unquestioned elements of post-transplant lymphomagenesis.

Fig. 28.1

Pathogenesis of post-transplant lymphoproliferative disease ( PTLD ) development. Shown are pathogenetic factors contributing to Epstein-Barr virus-driven PTLD development in the context of immunosuppression. EBV , Epstein-Barr virus; HLA , human leukocyte antigen.

Epstein-Barr Virus Infection

Epstein-Barr virus (EBV; human herpesvirus 4 [HHV-4]) is a human oncovirus belonging to the group of gamma herpesviruses. Primary infection with EBV usually occurs during childhood or adolescence, and by the age of 30 years, more than 90% of the population have acquired a persistent latent EBV infection of B cells. In addition, EBV can persist in salivary gland ductal cells. EBV particles are transmitted in the saliva fluid and use complement component 3d/EBV receptor 2 (CD21) for infecting B cells. Following B-cell infection, EBV establishes a nonproductive (latent) infection that is divided into four types—latency types 0 to 3—characterized by distinct viral gene expression profiles. On specific stimulation, EBV may switch into a productive (lytic) mode of infection, in which viral progeny is produced by the infected cell. EBV encodes latent membrane proteins (LMPs), Epstein-Barr nuclear antigens (EBNAs), other proteins, and regulatory noncoding RNA molecules, such as EBV-encoded small RNA (EBER), whose expression depends on the latency type of EBV infection.

Epstein-Barr Virus–Driven B-Cell Proliferation

In vitro EBV infection of B cells results in the outgrowth of immortalized lymphoblastoid B-cell lines, which express the latency type III program. This so-called growth program is characterized by the expression of nine proteins, LMP1, isoforms LMP2A and LMP2B as well as six EBNAs. These mimic external growth signals and inhibit apoptosis (LMP1 and LMP2A) or directly regulate gene expression (EBNA2, EBNA3c), thereby driving the infected cell into proliferation. In type II latency (default program), EBV gene expression is limited to the LMPs and EBNA1. EBV here supplies the infected B cell with signals, which are usually received on antigen contact in the germinal center. These signals drive the infected cell toward the memory B-cell stage. In type I latency, only EBNA1 , a gene required to maintain the viral genome during mitosis, is expressed. In latency type 0, no EBV protein is expressed in the infected cell.

Impaired Control of Epstein-Barr Virus–Induced B-Cell Proliferation by Epstein-Barr Virus–Specific T Cells

EBV-infected B-cells normally induce strong EBV-specific CD8 + and CD4 + T-cell responses, which control the proliferation of infected B cells in vitro and in vivo . The T-cell response is directed against a broad set of viral gene products expressed during the latent and lytic cycles of EBV. Pharmacological immunosuppression leads to impaired T-cell responses in vivo and therefore greatly increases the risk of uncontrolled B-cell proliferation. It is not entirely clear which T-cell populations confer protection against lymphoma development, but animal studies point to the importance of CD4 + T cells. Clinical success using transfer of EBV-specific T cells have indicated that latent antigens (EBNA1-3, LMP2) are targets of protective immune responses.

Genetic Hits and Additional Factors

Despite its unquestionable role, EBV infection alone may not be sufficient to induce PTLD in all cases. EBV plays a pivotal role, especially in early PTLD development, during the first post-transplantation year. Under continued immunosuppression, cells displaying other genetic alterations may escape immunosurveillance, and oncogenic mutations drive PTLD development. Some characteristic mutations (e.g., c-MYC translocations in Burkitt lymphoma or Burkitt PTLD ) have been detected in EBV-positive (EBV +) and EBV-negative (EBV-) monomorphic PTLD patients. Other cytogenetic defects involve chromosome segments 1q11-21, 14q32, 16p13, 11q23-24, and 18q21 in high-grade B-cell lymphoma PTLD. Upregulation of BCL2 (18q21) and BCL6 (3q27) are typical defects. Recently, several genetic alterations have been detected in T- and natural killer (NK)-cell PTLD, including inactivating mutations of deletions or the tumor suppressor gene TP53 (17p13). If and how these genetic alterations collaborate with EBV in B-cell transformation and lymphomagenesis remains unknown. Recent studies focus on gene expression patterns of different PTLD subtypes and the microenvironment (summarized by Morscio and Tousseyn ).

Origin of Post-transplant Lymphoproliferative Disease

Most cases of PTLD in recipients of solid organ transplantation are derived from recipient cells. However, especially after liver transplantation (LT), donor-derived PTLDs account for a significant proportion, possibly because of the transplantation of large amounts of donor B cells with the graft. A short tandem repeat (STR) polymerase chain reaction (PCR) assay or, if applicable, XY chromosome analysis, can easily reveal the origin of the PTLD. Donor-derived PTLDs seem to involve the graft organ preferentially.

Early and Late Post-transplant Lymphoproliferative Disease Development

In principle, all PTLD subtypes can manifest at any time after transplantation, even after a few weeks or many years. However, there are two clusters of PTLD onset—during the first year after transplantation (30%-40%, termed early PTLD ) and thereafter with an accumulation during the third to fourth post-transplantation year ( Fig. 28.2 ; data from the German Ped-PTLD registry). Early PTLD is almost exclusively EBV-driven and manifests as polymorphic or classic B-cell PTLD, whereas Burkitt lymphoma or classic Hodgkin disease PTLD is a late event after transplantation.

Fig. 28.2

Time between solid organ transplantation and post-transplantation lymphoproliferative disease onset. Green bars represent the liver transplant recipients; grey bars represent recipients of other solid organ grafts.

(Data from the German Ped-PTLD registry [ n = 225 patients]; from Maecker-Kolhoff B, unpublished).

Histopathological Classification

PTLDs are grouped as a separate entity in the 2016 revised WHO classification of lymphoid tumors ( Table 28.1 ). Nondestructive PTLD (formerly termed early-lesion PTLD ) are morphologically indistinguishable from reactive lymphoproliferation in nontransplanted patients. Whereas polymorphic PTLDs are only found in immunocompromised patients, lymphomas from the monomorphic PTLD group are morphologically and genetically indistinguishable from their counterparts in immunocompetent individuals.

Table 28.1

Classification of post-transplant lymphoproliferative disease according to the 2016 revision of the WHO classification

(Modified from Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood . 2016;127(20):2375-2390.)

Type Features
Nondestructive post-transplant lymphoproliferative disease (PTLD) (former early lesion) Plasmacytic hyperplasia, infectious mononucleosis like PTLD, fluoride follicular hyperplasia
Polymorphic PTLD B-cell origin, T-cell origin
Monomorphic PTLD Aggressive B-cell type

  • Diffuse, large, B-cell lymphoma (DLBCL)

  • Plasmablastic lymphoma

  • Burkitt, Burkitt-like lymphoma

T-cell, natural killer cell type
Classic Hodgkin lymphoma PTLD CD15 +, CD30 +

According to the 2016 revision of the WHO classification.

Tissue sampling for histology, immunohistochemistry, EBER in situ hybridization (ISH), PCR analysis of clonality, and fluorescence in situ hybridization (FISH) is mandatory for diagnosis. In principle, EBV-negative PTLD and EBV reactivation can coexist. Therefore, only direct detection of EBER by ISH or EBV proteins by immunohistochemistry in the tumor cells proves EBV association, but serum detection of EBV per se does not allow an EBV + PTLD to be found definitively.

Regarding PCR, the following pitfalls should be taken into account: (1) technical pseudomonoclonality because of a small amount of analyzed cells (e.g., biopsy specimen); (2) technical pseudopolyclonality because of hypermutation of the corresponding immunoglobulin (immunoglobulin heavy chain, IgH) or T-cell receptor (TCR) gene segments (i.e., PCR primers can no longer bind to the altered DNA sequence but detect the polyclonal background); and (3) transient dominant proliferation of one clone or oligoclonality.

Pitfalls of FISH analysis can be few tumor cells intermingled in a background of predominant reactive cells, such as lymphocyte-rich large B-cell lymphoma PTLD or masked tumor cells because of superimposed granulocytic inflammation and/or necrosis. FISH is usually not helpful for discriminating nondestructive PTLD from other types of PTLD.

Nondestructive PTLDs ( Fig. 28.3 A ) form masses, which histologically consist of follicular lymphatic hyperplasia, typically with increased number of plasma cells with some EBV + cells or no EBV-infected cells. Architecture of the lymphoid organ is typically retained. In some cases, subepithelial EBV + blasts and ulcerations of the tonsil surface indicate infectious mononucleosis-like nondestructive PTLD. Conventional histology is often sufficient for diagnosis but can be complemented by immunohistochemistry (e.g., CD3, CD20, BCL2, Ki67, kappa, lambda), EBER ISH, and PCR.

Fig. 28.3

Histopathology, immunohistochemistry, and molecular pathology of PTLD. (A) Non-destructive PTLD, follicular hyperplasia in tonsil. (B-E) Polymorphic PTLD with effacement of follicular organization (B), mixed proliferation of T-cells (CD3) and B-cells/plasma cells (CD79a) with few activated blasts but no diffuse blast infiltration (E). (F-I) Diffuse large B-cell PTLD with diffuse blast infiltration (F). Note that EBER is positive in all blast (G) while LMP1 protein is detected in only a small subfraction of blasts (H). CD20 can be expressed in all blasts or, as in this case, in a subfraction, either due to plasmablastic differentiation and/or antecedent rituximab therapy (I). (J) Burkitt PTLD with c-MYC rearrangement with FISH split signals (insert). (K, L) T cell PTLD (K) with CD3+ medium sized blasts (L). (M) Hodgkin PTLD with typical Hodgkin blasts with enlarged nucleoli (arrows).

Polymorphic PTLDs (see Fig. 28.3 B-F) are characterized by a mixed proliferation of B cells, plasma cells, and T cells. In contrast to nondestructive PTLDs, the histoarchitecture is disturbed, with diffuse effacement of follicular organization. The criteria for the diagnosis of any other lymphoma must not be met. In particular, T cell-rich diffuse large B-cell lymphomas and Hodgkin lymphomas should be excluded. Immunohistochemistry, EBER ISH, and PCR for clonality analysis should be carried out, but FISH is often not helpful.

Monomorphic PTLDs are divided into B-cell type lymphomas, most often diffuse large B-cell lymphomas (see Fig. 28.3 G-J) and rarer Burkitt lymphomas (see Fig. 28.3 K), plasmablastic lymphomas and plasmacytomas, T-cell and NK-cell type lymphomas (see Fig. 28.3 L, M). T-cell lymphomas include low- and high-grade subtypes, whereas low-grade indolent B-cell lymphomas are considered to be incidental; these are actually rare in transplant patients, in particular in children. CD30 +/CD15 + classic Hodgkin-type PTLDs (see Fig. 28.3 N) are considered to be a separate group; T-cell–rich, Hodgkin-like PTLDs with CD20 +, CD30 +, CD15- blasts are considered more likely to be monomorphic B-cell PTLDs. Post-transplantation acute lymphoblastic leukemias are not explicitly included in the WHO classification; they are extremely rare but are possible complications.

Approximately 60% to 70% of pediatric PTLDs and 50% of adult PTLDs are EBV +. The EBV-association is most prevalent in early PTLD because almost all cases detected during the first year after transplantation are EBV +. In EBV + cases, the virus-mediated antiapoptotic and promitotic cell deregulation facilitates uncontrolled proliferation. If EBV +, latency types in EBER + monomorphic PTLD are as follows:

  • Burkitt PTLDs are EBNA2-/LMP1- (latency type I)

  • CD30 +/CD15 + Hodgkin lymphoma PTLDs are EBNA2-/LMP1 + (latency type II)

  • High grade B-cell PTLDs are EBNA2 +/LMP1 + (latency type III)

Note that EBER ISH is more sensitive than EBV protein detection by immunohistochemistry, because all EBV-infected cells are usually EBER + but only a subfraction expresses EBV proteins such as LMP1 (see Fig. 28.3 H, I). Evaluation of CD20 and CD30 by immunohistochemistry and c-MYC rearrangement by FISH are important for therapy stratification, whereas evaluation of EBV proteins currently has little therapeutic impact, with the exception of EBV-directed cellular therapy.

The manifestation of concurrent or sequential B- and T-cell PTLDs, or nondestructive lesions, polymorphic, and/or monomorphic PTLDs is rare but has been described in some patients. These events seem to be the result of simultaneous independent lymphomagenesis rather than evolution of a sequence of related tumors. There is no evidence that nondestructive PTLDs are early lesions in terms of precursor lesions for aggressive PTLDs.

Incidence and Risk Factors in Pediatric Liver Transplantation

Incidence of Post-transplant Lymphoproliferative Disease

The incidence of PTLD varies greatly among different solid- organ transplant (SOT) recipients—from 1% to 2% after pediatric renal transplantation and up to 30% in recipients of heart, lung, or gastrointestinal organs. In pediatric liver transplant (LT) recipients, 2% to 5% of patients will ultimately develop PTLD. In retrospective analyses, multiple risk factors have been proposed. It is well accepted that transplantation from an EBV-positive donor into an EBV-naïve recipient constitutes a high-risk situation because primary infection with EBV occurs under intense pharmacological immunosuppression.

Risk Factors


The contribution of individual immunosuppressants to PTLD development has been the focus of intense investigation. T-cell–depleting antibodies used in some cases for induction therapy (e.g., antithymocyte globulin [ATG] or orthoclone OKT3 [muromonab-CD3]) may slightly increase the risk of PTLD development, although that is controversial. High doses of the calcineurin inhibitor tacrolimus seem to facilitate PTLD development, but the relative risk of other drugs is controversial in various studies. Inhibitors of mammalian target of rapamycin (mTOR) have been shown in vitro to inhibit the outgrowth of EBV-transformed B-cell lines, but whether this effects translates into clinical benefit needs to be evaluated in clinical trials.

Human Leukocyte Antigen Association

The risk of PTLD development has been attributed to certain, mainly class I, human leukocyte antigen (HLA) alleles. However, data from retrospective testing studies have yielded conflicting results. In a large cohort study, HLA-A02 homozygosity was found to be protective against EBV + Hodgkin disease, whereas no association could be detected in EBV + PTLDs after organ transplantation.

Other Risk Factors

Several other factors have been debated for their contribution to the PTLD risk. Negative cytomegalovirus (CMV) status at transplantation has been recognized as a risk factor for developing PTLD. Interestingly, in a large cohort study by Opelz and colleagues, CMV prophylaxis using CMV hyperimmunoglobulin significantly protected against PTLD development during the first year after renal transplantation.


Clinical Symptoms

The clinical presentation of PTLD is associated with the site of the PTLD manifestation. It may present as classic lymphadenopathy, hepatomegaly, and/or splenomegaly, but often is nonspecific (e.g., pain, persistent or recurrent fever, night sweats, weight loss, general malaise, graft organ or recipient organ dysfunction), especially in patients with extranodal involvement. Visible masses can be directly observed in oral lesions, in particular enlarged tonsils or mucosal ulcerations. Two-thirds of tonsil tumors are nondestructive PTLDs, one-third are polymorphic or monomorphic PTLDs; extratonsillar tumors of the oral cavity are mainly monomorphic PTLDs. The main extranodal site is the gastrointestinal tract, which may lead to nausea, diarrhea, abdominal pain, and/or failure to thrive. Early-onset PTLDs manifest more often as extranodal tumors and involve the allograft.

Biopsy and Histology

Diagnostic procedures aim at establishing the diagnosis of PTLD and evaluating the dissemination. A diagnostic algorithm is depicted in Fig. 28.4 . Pathological evaluation of malignant effusion cells (e.g., ascites, pleural, or pericardial effusion) or endoscopic, laparoscopic, or surgical biopsy is mandatory for securing the PTLD diagnosis and excluding main differential diagnoses. The following differential diagnosis should be considered :

  • Benign reactive hyperplasia

  • Lymphohistiocytic inflammations other than nondestructive PTLDs (e.g., CMV infection, myocobacteriosis)

  • Granulocytic inflammations

  • Rejection

  • Carcinomas

  • Kaposi sarcomas or rare EBV-associated post-transplantation smooth muscle tumors

Feb 23, 2021 | Posted by in HEPATOPANCREATOBILIARY | Comments Off on Post-transplant Lymphoproliferative Disease

Full access? Get Clinical Tree

Get Clinical Tree app for offline access